Abstract 2054P
Background
Little is known about metastatic cancer patients who are hospitalized at diagnosis because of impaired performance status and/or severe symptoms. This study aims to explore their prognosis and the effect of systemic anti-neoplastic treatment (SANT) initiation on their outcomes.
Methods
A prospective multicentric study of adult inpatients with a newly diagnosed metastatic solid tumor was conducted in seven cancer-facilities in France. During a three-month follow-up, socio-demographic characteristics, response rate and duration of response for patients receiving SANT, length of hospital stay and survival were collected. Correlation with clinical prognostic and predictive factors was analyzed.
Results
107 patients were included from November 2021 to April 2022. Seventy-four (69%) underwent SANT. Median overall survival was 1.7 months for the entire cohort. Forty (37%) were alive at 3 months, including 39 patients that started SANT. Factors associated with the initiation of a SANT were young age (OR=0,94 [0,90; 0,98]), low Charlson Comorbidity Index (OR=0,56 [0,42; 0,73]), SANT initiated at patient’s or caregiver’s request (OR=0,07 [0,02; 0,17] and 0,17 [0,06; 0,42], respectively). Patients with biomarker-based targeted therapy had better outcomes at 3 months, while survival of patients treated with exclusive immunotherapy was poor. PALLIA-10 score superior to 5 was a significant predictive factor for mortality (HR=3,24; p<0,001).
Conclusions
Metastatic cancer patients hospitalized at the time of diagnosis share a similar poor survival. The initiation of SANT does not always impact their outcomes. Larger prospective studies with longer follow-up are needed to better assess the effect of SANT in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ICANS - Institut de Cancérologie Strasbourg Europe.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06